Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perumal, M.
Right arrow Articles by Aboagye, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perumal, M.
Right arrow Articles by Aboagye, E. O.
[Cancer Research 66, 8558-8564, September 1, 2006]
© 2006 American Association for Cancer Research


Cell, Tumor, and Stem Cell Biology

Redistribution of Nucleoside Transporters to the Cell Membrane Provides a Novel Approach for Imaging Thymidylate Synthase Inhibition by Positron Emission Tomography

Meg Perumal1, Radhakrishna G. Pillai1, Henryk Barthel1,2, Julius Leyton1, John R. Latigo1, Martin Forster3, Fraser Mitchell3, Ann L. Jackman3 and Eric O. Aboagye1

1 Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom; 2 Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; and 3 Section of Medicine, Institute of Cancer Research, Surrey, United Kingdom

Requests for reprints: Eric O. Aboagye, Molecular Therapy Group, Faculty of Medicine, Imperial College London, Clinical Sciences Centre, Medical Research Council Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom. Phone: 44-20-8383-3759; Fax: 44-20-8383-2027; E-mail: eric.aboagye{at}imperial.ac.uk.

Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a need to develop noninvasive methods for assessing thymidylate synthase inhibition in tumors. The aim of this study was to assess the potential of 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography (PET) for early measurement of thymidylate synthase inhibition and to elucidate the cellular mechanisms involved. Radiation-induced fibrosarcoma-1 tumor-bearing mice were injected with a single i.p. dose of the thymidylate synthase inhibitor 5-fluorouracil (5-FU; 165 mg/kg) and imaged by [18F]FLT-PET at 1 to 2 hours after treatment. Deoxyuridine, thymidine kinase 1 (cytoplasmic thymidine kinase; EC2.7.1.21), and ATP levels in excised tumors were measured. Cellular assays for membrane transport were also done. There was a 1.8-fold increase in the 60-minute [18F]FLT tumor/heart radioactivity ratio in drug-treated mice compared with vehicle controls (P = 0.0016). Plasma and tumor deoxyuridine levels increased significantly but thymidine kinase and ATP levels were unchanged. Whole-cell assays implicated a (low level) functional role for the type-1 equilibrative nucleoside transporter (ENT). There was an increase in type-1 ENT-binding sites per cell from 49,110 in untreated cells to 73,142 (P = 0.03) in cells treated with 10 µg/mL 5-FU for 2 hours, without a change in transporter affinity (P = 0.41). We conclude that [18F]FLT-PET can be used to measure thymidylate synthase inhibition as early as 1 to 2 hours after treatment with 5-FU by a mechanism involving redistribution of nucleoside transporters to the plasma membrane. (Cancer Res 2006; 66(17): 8558-64)




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. G. Pillai, M. Forster, M. Perumal, F. Mitchell, J. Leyton, F. I. Aibgirhio, O. Golovko, A. L. Jackman, and E. O. Aboagye
Imaging Pharmacodynamics of the {alpha}-Folate Receptor-Targeted Thymidylate Synthase Inhibitor BGC 945
Cancer Res., May 15, 2008; 68(10): 3827 - 3834.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al.
Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine
Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Mitsuoka, S. Miyoshi, Y. Kato, Y. Murakami, R. Utsumi, Y. Kubo, A. Noda, Y. Nakamura, S. Nishimura, and A. Tsuji
Cancer Detection Using a PET Tracer, 11C-Glycylsarcosine, Targeted to H+/Peptide Transporter
J. Nucl. Med., April 1, 2008; 49(4): 615 - 622.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Herrmann, K. Ott, A. K. Buck, F. Lordick, D. Wilhelm, M. Souvatzoglou, K. Becker, T. Schuster, H.-J. Wester, J. R. Siewert, et al.
Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis
J. Nucl. Med., December 1, 2007; 48(12): 1945 - 1950.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.